Takaisin Tulosta

Key findings - Hormonal treatment combined with chemotherapy

Additional information
EAU guideline panel
16.4.2025
Table 1. Key findings - Hormonal treatment combined with chemotherapy
ADT = androgen deprivation therapy; ECOG = Eastern Cooperative Oncology Group; FU = follow-up; HR = hazard ratio; ISUP = International Society for Urological Pathology; mo = month; n = number of patients; OS = overall survival; P = prednisone; PSA-DT = prostate-specific antigen-doubling time.
STAMPEDE «James ND, Sydes MR, Clarke NW ym. Addition of doce...»1, «Clarke NW, Ali A, Ingleby FC ym. Addition of docet...»2 GETUG «Gravis G, Fizazi K, Joly F ym. Androgen-deprivatio...»3 CHAARTED «Sweeney CJ, Chen YH, Carducci M ym. Chemohormonal ...»4, «Kyriakopoulos CE, Chen YH, Carducci MA ym. Chemoho...»5
ADT ADT + Docetaxel + P ADT ADT + Docetaxel ADT ADT + Docetaxel
N 1,184 592 193 192 393 397
Newly
diagnosed M+
58% 59% 75% 67% 73% 73%
Key inclusion
Criteria
Patients scheduled for long-term
ADT
newly diagnosed M1 or N+ situations
locally advanced (at least two of cT3 cT4, ISUP grade ≥ 4, PSA ≥ 40 ng/mL)
relapsing locally treated disease with a PSA > 4 ng/mL and a PSA-DT < 6 mo.
or PSA > 20 ng/mL,
or nodal
or metastatic relapse
Metastatic disease
Karnofsky score ≥ 70%
Metastatic disease
ECOG PS 0, 1 or 2
Primary
objective
OS OS OS
Median follow
up (mo)
43; 78.2 (update M1) 50 54 (update)
HR (95% CI) 0.78 (0.66–0.93) 1.01 (0.75–1.36) 0.72 (0.59–0.89)
M1 only
N 1,086 - -
HR (95% CI) 0.81 (0.69–0.95) - -

References

  1. James ND, Sydes MR, Clarke NW ym. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77 «PMID: 26719232»PubMed
  2. Clarke NW, Ali A, Ingleby FC ym. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019;30:1992-2003 «PMID: 31560068»PubMed
  3. Gravis G, Fizazi K, Joly F ym. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149-58 «PMID: 23306100»PubMed
  4. Sweeney CJ, Chen YH, Carducci M ym. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015;373:737-46 «PMID: 26244877»PubMed
  5. Kyriakopoulos CE, Chen YH, Carducci MA ym. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2018;36:1080-1087 «PMID: 29384722»PubMed